Wave Life Sciences Ltd.
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Pipeline Updates
Summary
Wave Life Sciences Ltd. announced its financial results for the third quarter ended September 30, 2025, and provided a business update. The company reported cash and cash equivalents of $196.2 million as of September 30, 2025, with additional $72.1 million in ATM proceeds and committed GSK milestones extending the expected cash runway into 2Q 2027. Wave Life Sciences highlighted significant progress in its clinical trials for obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease. The company also shared financial highlights including revenue of $7.6 million for Q3 2025, compared to a loss of $7.7 million in Q3 2024, and a net loss of $53.9 million for Q3 2025.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents